Share
HOME > ABOUT US | FINANCIALS
HOME
OUR TECHNOLOGY

About Our Technology

Slowing Antibiotic Resistance

NanoLogix and Conventional Petri

NanoLogix and Polymerase Chain Reaction (PCR)

NanoLogix and Flow Cytometry

PRODUCTS

Product Overview

BioNanoPore

BioNanoFilter

TSA-EL Petri Plates

Quick Test Kits

Quality Documents

TEST RESULTS
INDUSTRY APPLICATIONS

Market Overview

Biodefense

Cosmetics

Environmental | Drinking Water Safety

Food & Beverage

Clinical Laboratories

Pharmaceuticals

Veterinary Medicine

NEWS & EVENTS

Videos

In the News

Updates

Press Releases

Events

RESOURCES
ABOUT US

Our Mission

Our Team

Our Facilities

Our History

Financials

CONTACT US

FINANCIALS

As of September 30, 2012, NanoLogix has 120,606,085 outstanding shares issued.

Please Note: 

  • Infectech is the former name of NanoLogix, Inc.
  • Included in each time period: Balance Sheet, Statement of Operations, Statement of Stockholders Deficit and Statement of Cash Flow.

2012-2011

March 31, 2012 and 2011

June 30, 2012 and 2011

September 30, 2012 and 2011

 

2011-2010

March 31, 2011 and 2010

June 30, 2011 and 2010

September 30, 2011 and 2010

December 31, 2011 and 2010

 

2010-2009

March 31, 2010 and 2009

June 30, 2010 and 2009

September 30, 2010 and 2009

December 31, 2010 and 2009

 

2009-2008

June 30, 2009 and 2008

September 30, 2009 and 2008

December 31, 2009 and 2008

 

2008-2007

December 31, 2008 and 2007

September 30, 2008 and 2007

June 30, 2008 and 2007

March 31, 2008 and 2007

 

2007-2006

December 31, 2007 and 2006

September 30, 2007 and 2006

June 30, 2007 and 2006

March 31, 2007 and 2006

 

2006-2005

Statement of Operations 2006 and 2005

Statement of Cash Flow 2006 and 2005

Balance Sheet 2006 and 2005

Statement of Shareholder Equity/Deficit 1989 through 2006

 

2005-2004

Statement of operations 2005 and 2004

Statement of Cash Flow 2005 and 2004

Balance Sheet 2005 and 2004

Statement of Shareholder Equity/Deficit 1989 and 2005

 

2004-2003

Statement of Operations 2004 and 2003

Statement of Cash Flow 2004

Balance Sheet 2004 and 2003

Statement of Shareholder Equity/Deficit 1989 through 2004

 

About NanoLogix

  • Our Mission
  • Our Team

    Management Team
    Board of Directors
    Scientific Advisory Board
  • Our Facilities
  • Our History
  • Financials

About NanoLogix

Our Mission

Our Team

Our Facilities

Our History

Financials

Contact Us

Technology

About Our Technology

Slowing Antibiotic Resistance

Conventional Petri

Polymerase Chain Reaction (PCR)

Flow Cytometry

 

Products

Product Overview

BioNanoPore™

BioNanoFilter™

Quick Test Kits

Test Results

Quality Documents

 

Industry Applications

Market Overview

Biodefense

Cosmetics

Environmental/Clean Water

Food & Beverage

Clinical Labs

Pharmaceuticals

Veterinary Medicine

News & Events

Videos

In the News

Updates

Press Releases

Events

NANOLOGIX | 330-534-0800 | info@nanologix.com | © NanoLogix 2011